IRIDEX Corporation (IRIX) Income Statement Analysis

See more : Tata Steel Limited (TTST.IL) Income Statement Analysis – Financial Results

Complete financial analysis of IRIDEX Corporation (IRIX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IRIDEX Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.

You may be interested

IRIDEX Corporation (IRIX)

Industry: Medical - Devices

Sector: Healthcare

Website: https://www.iridex.com

About IRIDEX Corporation

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995
Revenue	51.87M	56.97M	53.90M	36.35M	43.45M	42.60M	41.59M	46.16M	41.76M	42.81M	38.27M	33.86M	33.16M	43.69M	43.21M	48.53M	55.53M	35.90M	37.03M	32.81M	31.70M	30.63M	27.28M	33.44M	26.76M	23.60M	18.10M	12.40M	8.80M
Cost of Revenue	30.06M	31.60M	31.07M	20.79M	25.51M	25.13M	26.09M	25.32M	21.80M	21.41M	19.69M	17.51M	16.87M	22.79M	22.94M	28.85M	31.25M	17.10M	18.85M	17.92M	17.63M	17.05M	14.21M	13.75M	10.97M	9.60M	7.20M	4.70M	2.70M
Gross Profit	21.81M	25.37M	22.83M	15.56M	17.94M	17.47M	15.50M	20.84M	19.95M	21.41M	18.59M	16.35M	16.29M	20.90M	20.27M	19.68M	24.28M	18.81M	18.18M	14.89M	14.07M	13.59M	13.07M	19.69M	15.79M	14.00M	10.90M	7.70M	6.10M
Gross Profit Ratio	42.04%	44.53%	42.36%	42.80%	41.29%	41.01%	37.27%	45.15%	47.78%	50.00%	48.56%	48.28%	49.13%	47.84%	46.92%	40.55%	43.73%	52.38%	49.08%	45.38%	44.39%	44.36%	47.92%	58.89%	59.01%	59.32%	60.22%	62.10%	69.32%
Research & Development	6.83M	7.18M	6.87M	3.28M	3.68M	4.01M	5.73M	5.37M	5.21M	4.63M	3.68M	4.39M	3.91M	3.81M	3.61M	4.01M	5.78M	5.51M	4.20M	4.51M	4.03M	4.32M	4.81M	5.27M	3.93M	3.10M	1.70M	1.30M	0.00
General & Administrative	8.75M	7.56M	8.86M	6.62M	8.38M	9.55M	8.26M	7.64M	5.55M	6.03M	5.02M	4.93M	4.26M	4.49M	4.87M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	16.24M	18.18M	14.64M	12.24M	14.85M	16.78M	14.54M	10.28M	8.90M	8.16M	7.72M	7.90M	7.46M	9.80M	9.27M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	24.99M	25.74M	23.50M	18.86M	23.23M	26.33M	22.80M	17.92M	14.45M	14.19M	12.74M	12.82M	11.72M	14.29M	14.15M	17.84M	27.93M	18.06M	12.17M	11.46M	10.09M	9.45M	10.25M	10.75M	9.22M	8.40M	6.10M	5.20M	4.60M
Other Expenses	0.00	60.00K	2.35M	280.00K	209.00K	92.00K	-107.00K	-91.00K	3.00K	-1.26M	-371.00K	-210.00K	0.00	0.00	0.00	5.36M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	31.81M	32.91M	30.36M	22.14M	26.91M	30.34M	28.53M	23.28M	19.67M	18.82M	15.95M	17.21M	14.36M	18.11M	17.76M	21.85M	48.40M	23.57M	16.37M	15.96M	14.12M	13.77M	15.06M	16.91M	13.97M	12.20M	8.20M	6.70M	4.70M
Cost & Expenses	61.88M	64.51M	61.44M	42.93M	52.42M	55.47M	54.62M	48.60M	41.47M	40.23M	35.64M	34.72M	31.23M	40.90M	40.69M	50.70M	79.65M	40.67M	35.22M	33.89M	31.75M	30.82M	29.26M	30.65M	24.94M	21.80M	15.40M	11.40M	7.40M
Interest Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	733.00K	528.00K	249.00K	159.00K	151.00K	378.00K	552.00K	0.00	0.00	0.00	0.00	0.00
Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.26M	371.00K	210.00K	296.00K	78.00K	237.00K	507.00K	644.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	2.03M	1.38M	803.00K	504.00K	688.00K	809.00K	858.00K	648.00K	522.00K	420.00K	490.00K	427.00K	410.00K	515.00K	899.00K	3.22M	3.82M	542.00K	435.00K	384.00K	703.00K	869.00K	859.00K	893.00K	817.00K	700.00K	400.00K	200.00K	100.00K
EBITDA	-7.98M	-6.10M	-6.73M	-6.08M	-8.29M	-12.06M	-12.17M	-1.80M	810.00K	3.01M	2.65M	267.00K	2.85M	4.11M	4.22M	-3.52M	-17.80M	-3.49M	2.24M	-373.00K	655.00K	688.00K	-1.13M	3.21M	2.29M	2.47M	3.03M	1.20M	1.50M
EBITDA Ratio	-15.38%	-13.24%	-13.98%	-18.11%	-20.66%	-30.21%	-31.66%	-5.04%	0.69%	6.04%	6.88%	-4.90%	7.07%	7.58%	5.83%	2.16%	-14.60%	-11.76%	6.06%	-2.32%	1.90%	2.34%	-4.32%	10.95%	9.55%	8.47%	13.81%	4.03%	15.91%
Operating Income	-10.01M	-7.54M	-7.53M	-6.58M	-8.97M	-12.87M	-12.89M	-2.57M	288.00K	2.59M	2.63M	-860.00K	1.93M	2.80M	2.52M	-7.54M	-24.12M	-4.77M	1.81M	-1.08M	-48.00K	-181.00K	-1.99M	2.79M	1.83M	1.80M	2.70M	1.00M	1.40M
Operating Income Ratio	-19.29%	-13.24%	-13.98%	-18.11%	-20.66%	-30.21%	-30.99%	-5.56%	0.69%	6.04%	6.88%	-2.54%	5.83%	6.40%	5.83%	-15.53%	-43.43%	-13.27%	4.89%	-3.28%	-0.15%	-0.59%	-7.29%	8.34%	6.82%	7.63%	14.92%	8.06%	15.91%
Total Other Income/Expenses	527.00K	60.00K	2.35M	280.00K	209.00K	92.00K	-107.00K	-91.00K	3.00K	-1.26M	-371.00K	-110.00K	504.00K	722.00K	563.00K	293.00K	1.86M	733.00K	528.00K	319.00K	212.00K	122.00K	426.00K	569.00K	556.00K	500.00K	600.00K	700.00K	100.00K
Income Before Tax	-9.48M	-7.48M	-5.19M	-6.30M	-8.77M	-12.78M	-13.00M	-2.66M	291.00K	1.33M	2.26M	-270.00K	2.44M	3.52M	3.08M	-7.24M	-22.26M	-4.03M	2.34M	-757.00K	164.00K	-59.00K	-1.56M	3.36M	2.38M	2.30M	3.30M	1.70M	1.50M
Income Before Tax Ratio	-18.28%	-13.13%	-9.62%	-17.34%	-20.17%	-29.99%	-31.24%	-5.75%	0.70%	3.11%	5.91%	-0.80%	7.35%	8.05%	7.13%	-14.93%	-40.08%	-11.23%	6.31%	-2.31%	0.52%	-0.19%	-5.73%	10.04%	8.90%	9.75%	18.23%	13.71%	17.05%
Income Tax Expense	90.00K	65.00K	40.00K	26.00K	48.00K	37.00K	-128.00K	9.06M	-183.00K	-8.71M	31.00K	-100.00K	297.00K	473.00K	496.00K	127.00K	13.00K	1.72M	666.00K	-355.00K	-207.00K	-209.00K	-962.00K	940.00K	763.00K	600.00K	1.20M	700.00K	500.00K
Net Income	-9.57M	-7.55M	-5.23M	-6.33M	-8.81M	-12.81M	-12.87M	-11.71M	474.00K	10.04M	2.23M	1.44M	2.61M	3.05M	2.59M	-7.37M	-22.27M	-5.75M	1.67M	-402.00K	371.00K	150.00K	-1.27M	2.42M	1.62M	1.70M	2.10M	1.00M	1.00M
Net Income Ratio	-18.45%	-13.25%	-9.69%	-17.41%	-20.28%	-30.08%	-30.94%	-25.38%	1.14%	23.45%	5.83%	4.25%	7.87%	6.97%	5.98%	-15.19%	-40.11%	-16.02%	4.51%	-1.23%	1.17%	0.49%	-4.67%	7.23%	6.05%	7.20%	11.60%	8.06%	11.36%
EPS	-0.59	-0.47	-0.34	-0.46	-0.64	-1.05	-1.11	-1.15	0.05	1.01	0.24	0.16	0.29	0.34	0.29	-0.84	-2.69	-0.75	0.23	-0.06	0.05	0.02	-0.19	0.36	0.25	0.27	0.33	0.16	0.78
EPS Diluted	-0.59	-0.47	-0.34	-0.46	-0.64	-1.05	-1.11	-1.15	0.05	0.97	0.22	0.16	0.26	0.30	0.29	-0.84	-2.69	-0.75	0.21	-0.06	0.05	0.02	-0.19	0.33	0.24	0.26	0.31	0.16	0.23
Weighted Avg Shares Out	16.13M	15.94M	15.42M	13.84M	13.71M	12.20M	11.56M	10.17M	9.96M	9.89M	9.25M	8.50M	8.96M	8.94M	8.84M	8.82M	8.29M	7.71M	7.41M	7.20M	7.42M	6.87M	6.76M	6.64M	6.50M	6.48M	6.41M	6.25M	4.29M
Weighted Avg Shares Out (Dil)	16.13M	15.94M	15.42M	13.84M	13.71M	12.20M	11.56M	10.17M	10.13M	10.36M	10.10M	8.94M	10.23M	10.13M	8.94M	8.82M	8.29M	7.71M	7.88M	7.20M	7.42M	6.93M	6.76M	7.29M	6.85M	6.77M	6.76M	6.25M	4.29M

Iridex: Q4 Earnings Insights

March 22, 2021benzinga.com

Shares of Iridex (NASDAQ:IRIX) decreased 0.4% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 90.91% year over year to ($0.01), which beat the estimate of ($0.10).

Iridex Announces Fourth Quarter and Full Year 2020 Financial Results

March 22, 2021globenewswire.com

MOUNTAIN VIEW, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter and year ended January 2, 2021.

Preview: Iridex's Earnings

March 19, 2021benzinga.com

Iridex (NASDAQ:IRIX) releases its next round of earnings this Monday, March 22. Here is Benzinga's essential guide to Iridex's Q4 earnings report.

Iridex (IRIX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

March 15, 2021zacks.com

Iridex (IRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Iridex Completes Transaction with Topcon Corporation

March 10, 2021globenewswire.com

MOUNTAIN VIEW, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that it has completed the previously announced transaction with...

Iridex to Report Fourth Quarter and Full Year 2020 Financial Results on March 22, 2021

March 8, 2021globenewswire.com

MOUNTAIN VIEW, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the fourth quarter...

IRIX Stock Price Increases Over 20% Pre-Market: Why It Happened

March 3, 2021pulse2.com

The stock price of IRIDEX Corporation (NASDAQ: IRIX) is trading at over 20% pre-market. This is why it happened.

Iridex Announces Strategic Collaboration with Topcon Corporation

March 2, 2021globenewswire.com

MOUNTAIN VIEW, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that it has entered into a strategic collaboration with...

IRIDEX Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2020

January 11, 2021globenewswire.com

MOUNTAIN VIEW, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today provided preliminary unaudited operational and financial results for the fourth quarter and full year ended January 2, 2021.